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G protein-coupled receptors (GPCRs) are flexible integral membrane proteins involved
in transmembrane signaling. Their involvement in many physiological processes makes
them interesting targets for drug development. Determination of the structure of
these receptors will help to design more specific drugs, however, their structural
characterization has so far been hampered by the low expression and their inherent
instability in detergents which made protein engineering indispensable for structural and
biophysical characterization. Several approaches to stabilize the receptors in a particular
conformation have led to breakthroughs in GPCR structure determination. These include
truncations of the flexible regions, stabilization by antibodies and nanobodies, fusion
partners, high affinity and covalently bound ligands as well as conformational stabilization
by mutagenesis. In this review we focus on stabilization of GPCRs by insertion of
point mutations, which lead to increased conformational and thermal stability as well as
improved expression levels. We summarize existing mutagenesis strategies with different
coverage of GPCR sequence space and depth of information, design and transferability
of mutations and the molecular basis for stabilization. We also discuss whether mutations
alter the structure and pharmacological properties of GPCRs.
Keywords: G protein-coupled receptors, GPCRs, conformational thermostabilization, protein engineering, alanine
scanning, pharmacology, stabilizing mutations
Introduction
G protein-coupled receptors (GPCRs) are integral membrane proteins that play a central role in
signaling pathways being key intermediaries between external stimuli and the intracellular signal-
ing cascades. They consist of a single polypeptide chain with seven transmembrane domains, an
extracellular N-terminus and an intracellular C-terminus. They are only found in eukaryotes with
over 800 different GPCRs identified in humans so far, 400 of which are non-olfactory receptors
(Fredriksson et al., 2003; Bjarnadóttir et al., 2006). GPCRs regulate vision, smell and taste as well as
many other physiological processes (Pierce et al., 2002). They interact with photons, proteins, hor-
mones, neurotransmitters, and small molecules. A GPCRmay bind several different ligands, which
induce distinct conformational changes (Deupi and Kobilka, 2007, 2010; Kobilka and Deupi, 2007).
Such changes lead to different signaling modes and altered biological responses.
Binding of the ligand on the extracellular side of a GPCR elicits a conformational change that
extends to the intracellular surface of the receptor and results in activation of heterotrimeric
G proteins by exchange of GDP for GTP in the Gα subunit, followed by dissociation of Gα
and Gβγ which results in a change in intracellular second messengers levels (Gilman, 1987;
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Oldham and Hamm, 2008). Subsequent hydrolysis of the GTP
returns the G protein to its inactive state.
For many years, only cellular and biochemical studies have
provided insight into GPCR function. Crystallization and struc-
ture determination, however, lagged behind, which is due to low
expression levels and the poor stability of GPCRs in detergents
(Warne et al., 2009). For a long time, GPCRs could not be crys-
tallized or the produced crystals did not diffract well enough for
structure determination. The first structure of a GPCR, the struc-
ture of bovine rhodopsin, was determined in 2000 (Palczewski
et al., 2000). Then it took until 2007 to get the structure of another
GPCR, human β2 adrenergic receptor (Cherezov et al., 2007;
Rasmussen et al., 2007; Rosenbaum et al., 2007).
To date, crystallization and subsequent structural characteri-
zation of GPCRs requires extensive protein engineering (Kobilka
and Schertler, 2008; Blois and Bowie, 2009; Tate and Schertler,
2009; Chun et al., 2012; Tate, 2012; Bertheleme et al., 2013; Scott
et al., 2013). The only exceptions are bovine and squid rhodopsin,
which could be extracted from their native source, where they
are present in high abundance. They do not require extensive
purification and are stable in detergents (Palczewski et al., 2000;
Murakami and Kouyama, 2008). On the other hand, the determi-
nation of the crystal structure of recombinantly produced bovine
rhodopsin in its partially deglycosylated form required a high fac-
tor of purification and the introduction of a stabilizing disulfide
bond between N terminus and extracellular loop 3 (Standfuss
et al., 2007). Current techniques for GPCR studies include pro-
tein engineering and conformational stabilization by replacement
of flexible loops, shortening of N- or C-termini or introduction of
stabilizing mutations. Fusion partners such as T4 lysozyme (T4L)
or thermostabilized cytochrome b562RIL (BRIL) have been used
to stabilize GPCRs, reduce flexibility and facilitate their crystal-
lization (Chun et al., 2012). Besides the stabilization of the recep-
tor, the important factors for the increase in the number of solved
structures are the addition of antibody Fab fragments, nanobod-
ies and the use of lipidic cubic phase crystallization (Rasmussen
et al., 2007, 2011a,b; Weis and Kobilka, 2008).
While there is a set of commonly used fusion partners avail-
able for stabilization of GPCRs, a new set of stabilizing muta-
tions had to be identified for each receptor so far. Stabilizing
mutations have been found using a variety of techniques includ-
ing random error-prone PCR or all-vs.-all mutation combined
with evolutionary approaches (Sarkar et al., 2008; Dodevski
and Plückthun, 2011; Schlinkmann and Plückthun, 2013; Scott
and Plückthun, 2013; Scott et al., 2014) and systematic ala-
nine scanning mutagenesis (Magnani et al., 2008; Serrano-
Vega et al., 2008; Shibata et al., 2009; Robertson et al., 2011;
Hollenstein et al., 2013; Doré et al., 2014; Hirozane et al.,
2014). Most commonly used assays for conformational, ther-
mal and detergent stability include radio-ligand binding assays,
fluorescence size-exclusion chromatography (FSEC) and fluo-
rescence activated cell sorting (FACS) with fluorescently-labeled
ligands. Recently, computational prediction approaches have
been suggested. They were used to validate existing exper-
imental alanine scanning data, but have yet to be verified
for new receptors (Chen et al., 2012b; Bhattacharya et al.,
2014).
Methods for Stabilization of Non-GPCR
Proteins
Stabilization by mutagenesis is widely employed for soluble pro-
teins and includes stabilization of industrial enzymes, antibod-
ies, and fluorescent proteins (Ahern et al., 1987; Arase et al.,
1993; Amin et al., 2004; Pédelacq et al., 2006; reviewed in Nielsen
and Borchert, 2000; Wörn and Plückthun, 2001; Ó’Fágáin, 2003).
These methods include semi-rational protein design using one or
multiple homologs of the target protein as a source of possible
thermostabilizing variants, random mutagenesis and scanning
mutagenesis.
Influence of single amino acid changes on protein stability has
been studied for barnase where mutations were shown to change
protein stability to different degrees ranging from +1.1 kcal/mol
to −1.1 kcal/mol. This stabilization energy corresponds to a
change in thermostability of approximately 3◦C for this protein.
Stabilization and destabilization are connected to a change in
hydrophobic surface buried in the folded state as well as a loss
or gain of favorable interactions. Several stabilizing mutations
decreased flexibility and thereby increased thermostability (Ser-
rano et al., 1993). Semi-rational as well as random mutagenesis
was tested for p53, resulting in higher stability and increased
half-life (Nikolova et al., 1998; Matsumura and Ellington, 1999).
Interestingly, the final quadruple mutant from semi-rational pro-
tein design and the triplemutant from randommutagenesis share
two mutations. Diacylglycerol kinase (DGK), an integral mem-
brane protein from Escherichia coli, has been stabilized by two
different approaches: random PCR mutagenesis and introduc-
tion of cysteine mutants (Lau et al., 1999; Zhou and Bowie, 2000).
The approaches included semi-rational protein design using one
or multiple homologs of the target protein as a source of possi-
ble thermostabilizing variants, use of disease-rescue mutations,
random mutagenesis and scanning mutagenesis. Analysis of sev-
eral studies on insertion of mutations indicated that approxi-
mately 10% of randomly insertedmutations stabilized the protein
(Bowie, 2001).
Stabilization of GPCRs by Point Mutations
and their Combination
Currently there is no clear design strategy for stabilization of
GPCRs by mutations. Therefore, stabilizing mutations have to
be identified experimentally by testing many different point
mutations in either one-by-one or by ensemble evolutionary
approaches. When single mutations are identified, they can be
combined to further increase the thermostability of the pro-
tein. The process of combining the mutations is also experimen-
tal because the effects of individual mutations are not always
additive and the structural basis for stabilization is not neces-
sarily obvious. However, some general observations have been
formulated. Effects of replacing residues which are neighbors in
sequence or structure usually do not lead to a further increase and
may even decrease the stability of the protein, as effects of single
mutations may cancel each other when combined. Combinations
of non-neighboring mutations may lead to a further stabilization,
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though the increase in stability is usually smaller than the
summed up stabilization effects conferred by single mutations
(Magnani et al., 2008; Serrano-Vega et al., 2008; Shibata et al.,
2009, 2013; Lebon et al., 2011a). It has been observed that muta-
tions stabilizing the agonist-bound state are more difficult to
combine as they may stabilize slightly different active conforma-
tions. In addition, active conformations are more open on the
intracellular side which may be more difficult to stabilize com-
pared to a more compact, less dynamic inactive state (Magnani
et al., 2008).
Alanine and Leucine Scanning
Mutagenesis
The major approach to finding single stabilizing mutations is an
exchange of all amino acids of the GPCR one by one. At the cur-
rent level of technology, all-vs.-all mutations would lead to too
many protein variants for individual analysis. Therefore, amino
acids are exchanged for only one amino acid, commonly ala-
nine. Alanine itself is exchanged for leucine. Alanine and leucine
are the amino acids of choice due to their high helix propensity
(Horovitz et al., 1992; Blaber et al., 1993) and the low probability
of steric hindrances due to their small size. Additionally, both ala-
nine and leucine show a high occurrence in α-helical membrane
proteins (Eilers et al., 2002).
Alanine scanning has been used for stabilization of turkey
β1-adrenergic receptor in the inactive conformation (Serrano-
Vega et al., 2008; Warne et al., 2009), human adenosine A2A
receptor (Magnani et al., 2008; Lebon et al., 2011a; Robert-
son et al., 2011), and rat neurotensin receptor NTR1 with and
without agonist bound (Shibata et al., 2009, 2013). Additional
leucine scanning mutagenesis combined with salt-bridge engi-
neering improved the turkey β1-adrenergic receptor further
(Miller and Tate, 2011). In addition, the structures of the class
C metabotropic glutamate receptor 5 transmembrane domain,
class B corticotropin-releasing factor receptor 1 and adenosine
A2A receptor in complex with different ligands were solved using
conformationally thermostabilized receptors generated by ala-
nine scanning (Doré et al., 2011, 2014; Hollenstein et al., 2013).
Finally, a recent mutagenesis study based on alanine/valine scan-
ning and exchange of tyrosine for alanine and phenylalanine lead
to thermostabilized FFA receptor 1 (Hirozane et al., 2014).
While alanine or leucine scanning could technically be done
on a wild type receptor, this has not been tried for GPCRs so
far. In turkey β1-adrenergic receptor N- and C-termini were
truncated and a mutation, C116L, was inserted. This led to an
increased expression level and improved solubilization which
might have been hindered by the extended C-terminal domain
(Warne et al., 2003; Serrano-Vega et al., 2008; Miller and Tate,
2011). In adenosine A2A receptor, the 96 C-terminal residues
were deleted in order to prevent proteolytic degradation upon
solubilization (Weiß and Grisshammer, 2002; Magnani et al.,
2008; Lebon et al., 2011a). Rat neurotensin receptor NTR1 was
N-terminally truncated to start at T43 (White et al., 2004; Shibata
et al., 2009, 2013).
Single alanine/leucine mutants have been expressed in
Escherichia coli, the cells were lysed and the receptors solubilized
using different detergents. Alanine scanning or generation of
stabilized receptors based on HEK293T cell expression was done
for M1 muscarinic receptor, metabotropic glutamate receptor 5
and corticotropin-releasing factor receptor 1 (Robertson et al.,
2011; Hollenstein et al., 2013; Doré et al., 2014). Thermostabil-
ity has been assessed by incubation of the mutant receptors at
the apparent melting temperature of the wild type and measure-
ment of retained ligand binding activity. It has to be noted that
the melting temperature varies significantly with the experiment
design, especially the length of time for which the receptor is
incubated at elevated temperatures and the detergent used for
the assay. Short chain detergents such as octyl glucoside (OG)
are more destabilizing since they create smaller micelles around
the protein which is favorable for crystallization. Longer chain
detergents such as dodecyl maltoside (DDM) preserve the native
structure and activity of the protein better but are not suitable for
vapor-diffusion crystallization. The use of detergents is further
discussed in several other papers (Rigaud et al., 1995; Kragh-
Hansen et al., 1998; Seddon et al., 2004; Privé, 2007; Linke, 2009;
Lichtenberg et al., 2013; Meyer et al., 2015).
Alanine scanning for stabilization of agonist- or antagonist-
bound state may benefit from the presence of ligand in the heat-
ing step. The presence of the ligand in the heating step resulted in
a different pool of stabilizing mutants for adenosine A2A recep-
tor (Lebon et al., 2011a). These mutations have shown a higher
thermostabilization than the mutants identified in the assay in
absence of ligand (Magnani et al., 2008). Presence of agonist may
favor selection of mutations which stabilize the agonist-bound
state without requiring a stable inactive state. To develop a recep-
tor which tolerates detergents in the apo-state for ligand-affinity
purification, ligand was omitted in the heating step (Shibata
et al., 2009). This ensures that the selected mutations stabilize the
apo-state.
A likely explanation for the identification of different mutants
depending on assay format is that ligands stabilize a certain con-
formation of the receptor. In the apo-state, however, the recep-
tor switches between several inactive and active conformations
(Bockenhauer et al., 2011). One could argue that agonist alone is
not sufficient to induce the fully active state in diffusible-ligand
activated GPCRs, at least for the β2-adrenergic receptor (Deupi
and Kobilka, 2007; Kobilka and Deupi, 2007; Yao et al., 2009),
but so far selection in the presence of G protein has not been
reported.
Mutants should show a significant increase in residual activity
after heating, usually 65–75% activity where the wild type retains
50% activity. However, higher thermostability does not necessar-
ily correlate with higher protein expression. Therefore, a minimal
expression limit should be set.
Although used in the initial screen, alanine and leucine may
not be the most stabilizing amino acids. Exchange of the alanine
or leucine for different amino acids of varying size and charge
has been advantageous for turkey β1-adrenergic receptor. One
third of the mutations could be further improved by exchange
for different amino acids (Serrano-Vega et al., 2008).
More commonly, the thermostabilizing mutations are com-
bined by either PCR with random mixes of primers leading
to a random combination of mutations (Magnani et al., 2008;
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Serrano-Vega et al., 2008), or by design. In the design approach,
the most thermostabilizing mutant is used as a base (a new
pseudo wild-type) and the other mutations are combined with
the base mutant, leading to the identification of the best double
mutant (Lebon et al., 2011a). The pool of additivemutations from
the first round is then combined with the best double mutant on
a one-by-one basis, until sufficient stabilization for subsequent
crystallization attempts is achieved (Lebon et al., 2011a).
Alanine scanning combined with radio-ligand binding does
not only identify stabilizing mutations but leads to a conforma-
tionally and thermally stabilized construct which can then be
used for crystallization and subsequent structure determination.
Turkey β1-adrenergic receptor was improved by insertion of six
point mutations which increased the apparent melting temper-
ature of the receptor by 21◦C. Addition of antagonist increased
the melting temperature of the stabilized receptor by another
2◦C while the Tm of non-stabilized receptor was increased by
6◦C. This suggests that the receptor is conformationally ther-
mostabilized in an inactive state, which is further confirmed
by decreased affinity for agonists while the antagonist binding
stays unaffected (Serrano-Vega et al., 2008). The mutation of the
palmitoylation site C3588.59A was done to avoid the possibility
of heterogeneous palmitoylation (Warne et al., 2008, 2009). Sta-
bilization of human adenosine A2A receptor led to an increased
thermostability of 9◦C for the agonist-stabilized receptor and
17◦C for the antagonist-stabilized receptor in their ligand-bound
forms (Magnani et al., 2008); a second alanine scanning of the
receptor led to a stability increase of 21.5◦C in presence of the
agonist NECA (Lebon et al., 2011a). Rat neurotensin 1 recep-
tor stability was increased by 13◦C in presence and 17◦C in
absence of ligands as compared to the base construct (Shibata
et al., 2009). The M1 muscarinic receptor stability was increased
by 18◦C (Robertson et al., 2011). All receptors showed increased
stability in short-chain detergents, which are considered harsher
than long-chain detergents. For adenosine A2A receptor, the final
construct was independent of the lipid cholesteryl hemisucci-
nate (CHS) (Magnani et al., 2008; Serrano-Vega et al., 2008;
Shibata et al., 2009; Robertson et al., 2011; Brueckner et al.,
2013).
Directed Evolution Approaches
An alternative to alanine scanning for thermostabilization of
receptors is directed evolution. The main difference between
scanning mutagenesis and directed evolution is the number of
mutations which can be screened using evolution methods; while
alanine scanning provides information on all generated muta-
tions (usually 300–2000), directed evolution is used to screen
more than a million mutations, but only selects the most sta-
ble and/or best expressing mutants. Directed evolution systems
have been previously used to increase functional expression
at the cell surface and stability in detergents (Sarkar et al.,
2008; Dodevski and Plückthun, 2011; Schlinkmann et al., 2012a;
Scott and Plückthun, 2013). All methods are based on selec-
tion of many GPCR variants harboring single point-mutations
for increased expression at the cell surface or stability in deter-
gents. E. coli is the host of choice for evolutionary methods due
to its transformation efficiency which allows rapid screening of
millions of mutants. However, all methods require a high-affinity
fluorescently-labeled ligand for selection of GPCR variants with
higher functional expression or stability.
Libraries of receptor variants can be generated by error-prone
PCR. Libraries are transformed and expressed in the inner mem-
brane of E. coli, the outer membrane is permeabilized to allow
binding of fluorescently-labeled ligand to receptors. The cells are
sorted by fluorescence -activated cell sorting (FACS), usually the
1% highest fluorescent cells are selected and multiple rounds of
FACS sorting may be used. The cell sorting allows selection for
the highest expression level at the cell surface without selecting
for non-functional receptors. An increased diversity can then be
achieved by rerandomization or shuﬄing by staggered extension
process (SteP) of the existing library and further rounds of FACS
sorting (Sarkar et al., 2008). This method has been employed to
stabilize rat neurotensin receptor 1, α1a-adrenergic receptor, α1b-
adrenergic receptor and tachykinin receptor NK1 (Sarkar et al.,
2008; Dodevski and Plückthun, 2011).
An approach that results in a higher diversity of receptors is
the generation of libraries for every amino acid position to be
tested. For each library, a certain amino acid position is replaced
by an NNN codon, which allows all 64 possible codons at this
position (Schlinkmann et al., 2012b). The selection process is
the same as for an error-prone PCR based library. Selected vari-
ants can then be combined by staggered extension process (StEP)
or, for a complete coverage of all possible combinations, a new
library containing all possible combinations can be generated
using Slonomics R© technology.
Another approach, cellular high-throughput encapsulation,
solubilization and screening (CHESS), allows direct selection of
detergent-solubilized mutants. A receptor library is expressed
in E. coli cells and the cells are encapsulated with polymers
leading to single-cell capsules each expressing a different receptor
variant. The receptors are solubilized with a chosen deter-
gent and incubated with a fluorescently-labeled ligand. Recep-
tors retaining their function after detergent solubilization can
then be selected by FACS (Scott and Plückthun, 2013; Scott
et al., 2014). The expression vectors from selected cells are
isolated, amplified and used for a further round of evolution.
CHESS led to the most stable NTR1 variant reported to date;
the construct termed NTR1-H4 showed a melting tempera-
ture of 57◦C in presence of fluorescently labeled neurotensin
while the variant generated by alanine scanning reached 43.7◦C
(Scott et al., 2014).
Directed evolution approaches with error-prone PCR have led
to receptors expressing 2–18 times as many receptors compared
to the wild-type GPCR. Higher initial expression levels (α1b-
adrenergic receptor, twofold increase) could not be increased as
much as very low initial expression levels (α1a-adrenergic recep-
tor, 18-fold increase) (Sarkar et al., 2008; Dodevski and Plück-
thun, 2011). Combined approaches with initial improvement of
rat neurotensin receptor 1 by error-prone PCR-based evolution
led to a variant with a 12-fold higher expression level (Dode-
vski and Plückthun, 2011). This variant was improved to 50-
fold increased expression compared to wild type using all-vs.-all
mutations (Schlinkmann et al., 2012b).
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FIGURE 1 | Timeline of GPCR structures based on conformational
thermostabilization by alanine scanning (blue) or directed evolution
(red) with their ligands (yellow). PDB IDs: 2VT4 (turkey β1-adrenergic
receptor), 2YDO (human adenosine A2A receptor), 4GRV (neurotensin recetor
1, conformationally stabilized), 4K5Y (corticotropin-releasing factor receptor 1),
4BV0 (neurotensin receptor 1, directed evolution), 4OR2 (metabotropic
glutamate receptor) and 4PHU (free fatty-acid receptor 1).
Structures solved after thermostabilization by alanine scan-
ning or directed evolution are represented in Figure 1 and
favorable mutations found in different receptors are shown in
Figure 2 and Supplementary Table S1. Alanine scanning iden-
tified approximately 90 mutations and 70 were found using
directed evolution. The identified mutations are distributed all
over the receptor sequence, including both the transmembrane
helices and loop regions. It is interesting to note that 15 muta-
tions (ca. 10%) overlap between sets of mutations derived by
two approaches. This number only refers to mutations in the
transmembrane parts because sequence conservation of the loop
regions is very weak, and, therefore, direct comparison of the
residue positions in different receptors is not always possible.
However, it has to be noted that a significant number of sta-
bilizing mutations was identified in the loop regions (ca. 30%),
as well as in the presumably unstructured C-terminus of the
receptor at the positions after the predicted helix 8. Given
that the majority of these mutations were identified in E. coli
based screens which lacks proteins interacting with the recep-
tors (e.g., arrestins), this strongly suggests that all of these posi-
tions are involved in stabilizing interactions and are in structured
environments.
Constitutively Active Mutants
For the majority of crystal structures, modified receptors with
little basal activity were used. Most receptors were bound to
inverse agonist or antagonist and correspond to receptors in
their inactive state (Deupi and Standfuss, 2011). Constitutively
active mutations, however, may conformationally stabilize the
active state of the receptor and may be useful for structural stud-
ies. These mutants are ubiquitously found among GPCRs and
are often related to different diseases (Schöneberg et al., 2004).
Although multiple mechanisms may link a mutation to a disease,
at least in some cases these mutations were shown to activate the
receptor in the absence of the agonist. There are several examples
of using constitutively active mutations for the structural studies
of rhodopsin.
Mutations of the two amino acids in the ligand binding pocket,
Lys2967.42 and Glu1133.28, lead to strong constitutive activa-
tion of opsin due to the perturbation of the salt bridge which
stabilizes the inactive ground state (Cohen et al., 1992; Robin-
son et al., 1992; Standfuss et al., 2008). A crystal structure of
E1133.28Q rhodopsin in complex with a peptide derived from
the C-terminus of the alpha subunit of the G protein transducin
(GαCT) represents an active state of rhodopsin (Standfuss et al.,
2011). A structure of the disease-inducing mutation G902.56D
shows pertubations of the same Lys2967.42-Glu1133.28 salt bridge
(Singhal et al., 2013). Constitutive activity of the M2576.40Y
mutant most probably stems from a stabilization of the open
G-protein binding pocket as suggested by its crystal structure
(Deupi et al., 2012).
The constitutively active mutants have also been shown to be
very promising for formation of the stable GPCR-G protein sig-
naling complex. The E1133.28Q mutant forms a rhodopsin Rho-
G-protein transducin (Gt) complex that is, opposite to the native
complex, stable in detergents (Xie et al., 2011). The M2576.40Y
mutant forms a very stable Rho-Gt and an even more stable
Rho-Gi complex which is superior to the E1133.28Q complex for
crystallization trials due to its higher detergent resistance and
long-term stability (Maeda et al., 2014).
Overall, it is likely that constitutively active mutants will have
a big impact on structure determination of signaling complexes
of rhodopsin and other GPCRs.
Computational Approaches
The emergence of the experimental data on GPCR stabiliza-
tion by mutagenesis, combined with crystallographic structures
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FIGURE 2 | Favorable mutations identified by alanine scanning (A) and
directed evolution (B) in presence of agonist (green), antagonist (red)
and in absence of ligand (yellow). Alanine scanning identified mutations
which increase the thermostability of receptors while retaining a minimal
expression level. Directed evolution detected mutations that increased
expression or thermostability, or both. Position of mutations is indicated by
Ballesteros-Weinstein numbering. Mutations found in multiple receptors are
indicated by double dots, those with high expression levels (=125% of
wild-type expression level, alanine scanning only) are shown as hexagons.
ECL and ICL stand for extracellular and intracellular loops, respectively.
of GPCRs, allows for the rationalization of the effects of muta-
tions on protein stability. More importantly, it allows for com-
putation prediction of stabilizing mutations. A very interesting
approach is to identify the metastable regions in the GPCRs,
which are responsible for their conformational flexibility, and to
stabilize these regions by improving side chain packing (Chen
et al., 2012b). Using wild type and stabilized turkey β1-adrenergic
receptor as starting points, the authors were able to predict
and experimentally confirm several mutations which significantly
increased the stability of both proteins. In addition of being able
to identify novel stabilizing mutations, this method also rational-
izes 70% of stabilizingmutations identified by alanine scanning of
turkey β1-adrenergic and A2A receptors. An alternative approach
to identify stabilizing mutations is based on generation of the
ensemble of conformations based on a homology model, and
the prediction of an average enthalpy around the mutation site
(Bhattacharya et al., 2014). This parameter was shown to cor-
relate relatively well with the observed stabilization effect of
mutations in turkey β1-adrenergic, A2A and NTR1 receptors. As
our understanding of the role of the individual amino acids in
GPCR structure and stability improves, and more experimental
data become available, the computational approaches to receptor
design will likely become more powerful and widely used in the
future.
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Methods for Assessment of Receptor
Stability
Radio-Ligand Binding
Radio-ligand binding as described in the alanine scanning section
is the most widely used high-throughput method for determi-
nation of stability, assessment of the percentage of receptor still
active after incubation at a given temperature and comparison
to the stability of the wild-type. One of the reasons for this is
the sensitivity of the method, the corresponding very low sample
requirements, and the ability to work with non-purified samples
and even membranes. On the other hand, this method depends
on the availability of the desired ligand labelled with either 3H or
125I.
Fluorescence
Fluorescently-labeled ligand can be used for high-throughput
stability tests in any given condition such as different detergent
solutions. The remaining ligand fluorescence after incubation
reflects how much receptor is still active after the incubation
period. The ligand fluorescence can be normalized by measur-
ing the fluorescence of a genetically-encoded fluorescent protein
such as GFP. The assay set-up is facilitated by a purification tag
which allows binding of the receptor to magnetic beads since
they can be easily transferred to assay and washing solutions.
The assay has been developed for neurotensin receptor 1 using
HiLyte Fluor 647-labeled neurotensin, GFP-labeled NTR1 for
receptor quantification and an Avi-tag for in vivo biotinylation
and capture on streptavidin-coated magnetic beads (Scott and
Plückthun, 2013; Scott et al., 2014).
A Fluorescence-Detection Size-Exclusion
Chromatography-Based Thermostability Assay
(FSEC-TS)
Traditional methods that evaluate protein stability require large
amounts of material, and are therefore ill-suited for medium-to-
high-throughput screening of membrane proteins (Hattori et al.,
2012). With this method the proteins can be analyzed in either
purified or unpurified form (solubilized lysates) and it allows
evaluatingmicrogram to nanogram amounts of samples. Unpuri-
fied target proteins need to be expressed as a GFP fusion, while for
the purified protein tryptophan fluorescence can be used. Puri-
fied or unpurified proteins are incubated over a range of tem-
peratures and then applied to a size-exclusion chromatography
column in line with a fluorescence detector to monitor GFP flu-
orescence from GFP-tagged proteins or tryptophan fluorescence
from endogenous Trp residues (Hattori et al., 2012). The results
provide an apparent melting temperature (Tm), which can be
used as a reference point to test the degree of protein thermosta-
bilization. This method also allows testing of different ligands,
ions, detergents on the thermostability of the receptor (Hattori
et al., 2012). Several proteins had their Tm determined in this way,
for example P2X4, GluCl (Hattori et al., 2012) as well as a number
of mutated and non-mutated proteins in the authors’ laboratory.
This method has also been used for the determination of Tm of
a complex RhoM257Y/Gi (Maeda et al., 2014).The main advan-
tage is that it can be used for small amounts of unpurified sample,
which saves time and sample that might be lost through the pro-
cess of purification. However, in this case the protein needs to be
fused to GFP and the throughput of the method is still relatively
low compared to some other methods currently used in this field.
While the experiments have been done mostly with GFP fusions
so far, other fluorescent fusions can also be used (e.g., RFP, YFP).
Differential Scanning Fluorimetry (DSF)
A faster method for determination of melting temperatures is dif-
ferential scanning fluorimetry (DSF) using 7-diethylamino-3-(4′-
maleimidylphenyl)-4-methylcoumarin (CPM) dye (Alexandrov
et al., 2008). CPM dye is a thiol-reactive probe which reacts with
cysteines once they are exposed. Upon binding to a cysteine, the
dye becomes fluorescent. Increasing fluorescence is therefore a
measure of protein unfolding. The method can be performed in
either a fluorescence spectrometer or, for a higher throughput, in
an RT-PCR machine equipped with the respective filters (365 nm
excitation, 460 nm detection). The method is fast and effective
and needs small (1–4µg) amounts of purified protein containing
reduced buried cysteines.
Homogeneous Time Resolved Fluorescence
A very promising alternative to the radio-ligand binding sta-
bility assay is an assay based on homogeneous time resolved
fluorescence (HTRF R©) (Degorce et al., 2009) between a
conformationally-specific 2D7 antibody recognizing the extracel-
lular loop 2 (ECL2) of the CCR5 receptor, labeled with a Eu3+-
cryptate donor, and a 1D4 antibody labeled with XL665 acceptor,
targeted to the C-terminus of the receptor. Dissociation of the
2D7 antibody upon protein unfolding resulted in a decrease of
the HTRF signal (Knepp et al., 2011). This assay allowed to mea-
sure protein stability change in the presence of a variety of lig-
ands, and its sensitivity is comparable to radio-ligand binding
assays.
Other Biophysical Methods
If the purified receptor is available in reasonable amounts (100µg
tomg scale) more conventional biophysical methods can be
applied. Since GPCRs have large alpha-helical content, circular
dichroism (CD) spectroscopy will be sensitive to protein unfold-
ing, and has been used to characterize olfactory receptor stability
(Cook et al., 2009; Corin et al., 2011).
Intrinsic tryptophan fluorescence has been used to determine
the thermostability of GPCRs in the authors’ laboratory and can
be used to measure their resistance to chemical denaturation
(Ross et al., 2015).
Chemical Denaturation
Chemical denaturation of GPCRs offers a convenient alternative
to temperature induced unfolding. To induce unfolding, the con-
centration of the denaturing agent, such as urea, guanidinium
chloride or harsh detergents such as SDS is gradually increased
(Zhou and Bowie, 2000; Zhou et al., 2001; Sehgal andOtzen, 2006;
McKibbin et al., 2009; Miller et al., 2009; Curnow et al., 2011;
Harris et al., 2014; Tastan et al., 2014).
For example, it is possible to deduce the binding constant
of a ligand to protein from the concentration dependence of
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FIGURE 3 | Molecular basis for stabilization by mutation of residues
involved in activation. Residues directly involved in GPCR activation (shown
as magenta sticks with Ballersteros-Weinstein numbers and the backbone
shown in gray), were identified by comparison of inactive and active state
structures. They form a continuous path between the ligand (yellow spheres)
and the effector binding site, mapped on the crystal structure of the complex
between human β2adrenergic receptor and the heterotrimeric Gs (cyan, PBD
ID 3SN6, Rasmussen et al., 2011b).
ligand- induced stabilization. Because chemical denaturation is
performed at a constant temperature, the measurement of the Kd
is straightforward (Ross et al., 2015).
Molecular Basis for Stabilization
Based on our comparison of inactive and active structures and
the current knowledge of the structural basis of GPCR activation
we suggest a classification of stabilizing mutations into four main
groups:
(i) Mutation of residues directly involved in the activation
mechanism. This group comprises the mutation of residues
which are responsible for stabilizing the active state upon
agonist binding and were identified by comparison of active
and inactive-state structures. These residues are oriented
toward the core of the transmembrane bundle and cre-
ate a continuous path between the ligand binding site and
the transducer binding site (Figure 3, Rasmussen et al.,
2011b). We hypothesize that mutation of these residues may
stabilize a particular, either active or inactive, state of the
TABLE 1 | Mutations identified in the activation path of class A GPCRs.
Ballesteros- Receptor Ligand Mutation Identified by
Weinstein type
number
3.40 Turkey β1-adrenergic
receptor
Antagonist I129V Alanine scanning
3.50 Rat neurotensin
receptor 1
Agonist R167L Directed evolution
5.42 Tachykinin receptor 1 Agonist C199G Directed evolution
Rat neurotensin
receptor 1
Agonist V240L Directed evolution
5.43 - - - -
5.46 Tachykinin receptor 1 Agonist I204T Directed evolution
5.54 Rat neurotensin
receptor 1
Agonist I253A Directed evolution
5.58 Turkey β1-adrenergic
receptor
Antagonist Y227A Alanine scanning
6.41 Adenosine A2A
receptor
Antagonist V239A Alanine scanning
6.44 Adenosine A2A
receptor
Agonist F242A Alanine scanning
7.39 α1A-adrenergic
receptor
Antagonist F312L Directed evolution
α1B-adrenergic
receptor
Antagonist F334L Directed evolution
7.43 Turkey β1-adrenergic
receptor
Antagonist A334L Alanine scanning
7.45 α1A-adrenergic
receptor
Antagonist N318H Directed evolution
7.53 Turkey β1-adrenergic
receptor
Antagonist Y343L Alanine scanning
These mutations may stabilize an agonist or an antagonist-bound state of the receptor.
receptor. The positions in the activation pathmay be used to
design conformationally stabilizing mutations for the inac-
tive or active state. Several mutations in these positions
have been identified by alanine scanning or directed evolu-
tion approaches (Table 1). Mutation of these residues may
modify the local energy minima of the inactive and active
states, and/or the energy barrier between them. This would
alter the equilibrium between the states, stabilizing a spe-
cific conformation. A representative example of this group
is Y2275.58A in turkey β1AR (Serrano-Vega et al., 2008).
This tyrosine is important for the activation mechanism of
GPCRs (Goncalves et al., 2010; Dror et al., 2011) as in the
active state it interacts with R3.50 and with Y7.53 through a
water-mediated hydrogen bond (Deupi et al., 2012), stabiliz-
ing the outward movement of helix 6. In rhodopsin, muta-
tion of Y5.58 to F leads to a less stable active state (Goncalves
et al., 2010). Similarly, its mutation to alanine in the β1AR
may destabilize the active conformation of the receptor, by
removing the possibility of interaction with R3.50 and Y7.53,
resulting in the observed stabilization of the inactive state.
(ii) Mutation of residues that are indirectly involved in the acti-
vation process. These residues would modulate the confor-
mation of the residues from the first group either through
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direct interactions or by influencing specific inter-helical
packing regions that affect the relative energy between the
side chain conformations of the residues in the first group. A
representative example is L3106.37A in NTR1 (White et al.,
2012; Shibata et al., 2013). A leucine at this position places
a bulky side chain between R3.50 and N5.58 (as observed in
the structure of many inactive GPCRs; approximately 80%
of Class A GPCRs have L/V/I at this position). Mutation
of this residue to alanine in the NTR1 alters the packing
between transmembrane helix 3 (TM3), TM5 and TM6 by
reducing the volume of the side chain. As a result, in the
structure of the thermostabilized NTR1 (White et al., 2012),
R3.50 features a “warped” conformation (possibly aided by
the neighboring mutation E166A3.49) that may reduce the
energy barrier for its interaction with N5.58, stabilizing an
active-like structure.
(iii) Mutation of residues facing lipids or detergent. These
mutations may influence the properties of the outer sur-
face of the receptor and change its interaction with the
lipid and detergent molecules. A representative example is
F3387.48M in tβ1AR (Serrano-Vega et al., 2008). In this case,
a rigid phenylalanine is replaced by the flexible side chain
of methionine which complements A7.44 one turn above,
resulting in a smoother surface to which lipids or detergent
may adjust with higher compatibility.
(iv) Mutation of residues responsible for local structural stabil-
ity. These residues are located, for instance, in the inter-
face between helices, or in the interface between helices
and loops, and their mutation may alter the structural or
dynamic properties of the local secondary structure. A rep-
resentative mutation is I551.46A in tβ1AR (Serrano-Vega
et al., 2008). This residue is located in the interface between
TM1, TM2, and TM7, and most GPCRs (approx. 90%) have
a small residue (G/A/S/T) in this position. In the crystal
structures of receptors with a small side chain at this posi-
tion (e.g. CCR5, PAR1, µ-OR), TM1 is closer to the rest of
the transmembrane bundle than when this residue contains
a bulky side chain (e.g., β1AR, β2AR, S1P1R). Thus, muta-
tion of this residue to alanine in the tβ1ARmight allow TM1
to come closer to the transmembrane bundle and improve
the packing with TM2 and TM7.
Rational Design and Transferability of
Mutations
Most thermostabilizing point mutations found in alanine scan-
ning approaches have been shown to stabilize either the inac-
tive or the active state. The two sets of mutations found
for human adenosine A2A receptor using either the ago-
nist 5′-N-ethylcarboxamidoadenosine (NECA) or the antagonist
ZM241385 contain 27 and 17 mutations, respectively. Only three
mutations were found to stabilize both conformations (Magnani
et al., 2008). This shows that the mutations found depend largely
on the ligand used for the stability assay, and, correspondingly, on
the conformation of the receptor. The sets of mutations found for
human adenosine A2A receptor, turkey β1-adrenergic receptor
and rat neurotensin receptor NTR1 do not overlap; transfer of
these mutations to other GPCRs might not lead to a stabilization
of the unliganded state but could have a stabilizing effect on the
respective liganded receptors.
One mutation, E1223.41W, identified in human β2-adrenergic
receptor has been shown to be transferable to different GPCRs
and increased thermostability as well as total expression level and
expression at the cell surface (Roth et al., 2008). In rhodopsin,
W1263.41 is the only residue in transmembrane (TM) domain 3
which contacts both TM4 and TM5. Since position 3.41 is not
conserved, introduction of a mutation is less likely to disturb the
overall fold of the receptor. The tryptophan at the TM3-TM4-
TM5 interface is thought to stabilize the conformationally flexible
TM5, and thereby increase thermostability and expression. The
effect on β1-adrenergic receptor was similar to thermostabiliza-
tion by addition of antagonist (Roth et al., 2008). Other muta-
tions of the E1223.41 residue also led to higher thermostability
and expression, especially E122Y and E122L. However, all muta-
tions showed a loss in affinity for the ligand. The mutation which
showed the highest increase in thermal stability has been suc-
cessfully transferred to the serotonin receptors 5-HT1B (L138W)
and 5-HT2B (M144W) as well as the CXCR4 chemokine receptor
(L125W) (Wu et al., 2010; Wacker et al., 2013; Wang et al., 2013)
and D3 dopamine receptor (L119W) (Chien et al., 2010). As pro-
posed by molecular modeling of human β2-adrenergic receptor
(hβ2AR), W3.41 stabilizes 5-HT1B, 5-HT2B and CXCR4 by its
interaction with P5.50 and the carbonyl of 5.46 (Figure 4). Since
conformational flexibility of TM5 is an inherent feature of class A
GPCRs, transfer of this mutation is likely to be successful (Roth
et al., 2008).
About 90 thermostabilizing mutations were identified in
GPCRs by alanine scanning so far, however, only two of these
mutations were predicted to be transferable to other receptors
(Serrano-Vega and Tate, 2009). The transferability of the muta-
tions has been tested on adrenergic receptors. Turkey β1AR
(tβ1AR) is 76% and 59% identical to human β1AR (hβ1AR)
and β2AR (hβ2AR) respectively (Serrano-Vega and Tate, 2009).
FIGURE 4 | Molecular basis of stabilization by mutation of the 3.41
position to tryptophan. The 3.41W mutation stabilizes 5-HT1B (green),
5-HT2B (light pink) and CXCR4 (blue) through its interaction with the proline in
position 5.50 and the carbonyl of the amino acid in position 5.45.
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For the comparison N- and C-termini were removed. All six
thermostabilizing mutations (referred to as the m23 mutations:
R68S, M90V, Y227A, A282L, F327A, and F338M) that were pre-
viously determined in tβ1AR were transferred en bloc to the
human receptors. The initial test of the thermostability of non-
mutated proteins showed that both β1 receptors prefer a lipid-
rich environment rather than just DDM, while hβ2AR is largely
insensitive to different DDM concentrations (Serrano-Vega and
Tate, 2009). Melting temperatures of the receptors with muta-
tions were increased by 21◦C, 17◦C, and 11◦C for tβ1AR, hβ1AR,
and hβ2AR, respectively. Since the optimal amino acid residues
required to stabilize the human receptors could be different from
those that stabilized turkey receptor, different residues were tried
at the six positions. While the majority of the mutants showed
similar or worse thermostability compared to the original m23
mutants, some exceptions were found (Serrano-Vega and Tate,
2009). The m23 thermostabilizing mutations preferentially stabi-
lized the turkey receptor in the antagonist bound conformation
and data show that they are affecting the conformation of human
receptors in a similar way (Serrano-Vega and Tate, 2009).
Generally, transfer of other mutations could be a possibility
for other closely related receptors or for mutations of residues
which show a high degree of identity or similarity between
different receptors.
Does Stabilization Alter the Structure of
Receptors?
Two rat neurotensin receptor 1 variants selected by CHESS
and a variant harboring 11 mutations uncovered by recom-
bination and evolution of position-specific libraries have been
crystallized (Schlinkmann et al., 2012a,b; Egloff et al., 2014).
All three structures are almost identical even though the sets
of mutations are different (overall RMSD = 0.4Å). In addition,
one variant was competent of G-protein activation, though at a
reduced level, ligand binding with native-like affinities and desen-
sitization. The structure looks like an inactive agonist-bound
conformation since TM6 did not move outwards, which agrees
well with the reduced G-protein activation observed and the fact
that R1673.50, a residue involved in the activation mechanism has
beenmutated to leucine. The T4L structure of NTR1 (White et al.,
2012, PDB ID 4GRV), supposedly in a semi-active conformation,
is very similar to the structures obtained by directed evolution.
They only differ at the intracellular ends of TM5 and 6 which
might be due to different degrees of activation and the fusion with
T4L (Figure 5A).
Two versions of turkey β1 adrenergic receptor, m23 and JM50
(PDB IDs 2VT4 and 4BVN), differ by three additional mutations
in the JM50 construct (Warne et al., 2008; Miller-Gallacher et al.,
2014). I1293.40V, a mutation in the transmembrane core, does not
alter the structure when compared to m23. D322K and Y343L
which are in the extracellular loop 3 and at the intracellular end of
TM7, respectively, change the structure by 1.5–2 Å. This change
is probably due to reduced dynamic properties of regions which
are generally more flexible. It can be concluded that the structural
influence of these mutations is marginal.
Three versions of human adenosine A2A receptor with con-
formationally thermostabilizing mutations, T4L- or bRIL-fusion
(PDB IDs 3PWH, 3EML, and 4EIY) and with the same inverse
agonist bound show very similar structures, differences are in
flexible parts only which means that the structure is not changed
by the stabilizingmutations (Figure 5B). One difference is a small
change at the intracellular side of TM5 which might be due to
FIGURE 5 | Comparison of GPCRs containing either a fusion protein or
thermostabilizing mutations. Structures of neurotensin receptor 1 (A) and
adenosine A2A receptor in the inactive (B) and active (C) state solved using
fusion-protein or point-mutagenesis approaches show high similarity [overall
RMSD = 0.95 Å (A) and 0.5 Å (B,C)]. The differences in helices five and six in
the two neurotensin receptor structures may be due to mutation of an amino
acid involved in activation, R1673.50L, in one receptor and the T4 lysozyme
fusion in the other receptor. PDB IDs: 3ZEV (NTR1, directed evolution), 4GRV
(NTR1, fusion with T4 lysozyme), 3PWH (A2A, antagonist-bound, with
thermostabilizing mutations), 3EML (A2A, antagonist-bound, T4 lysozyme
fusion), 3QAK (A2A, with agonist UK-432097 and T4 lysozyme) and 2YDO
(with agonist adenosine and thermostabilizing mutations).
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fusion partners. The agonist-bound A2A structures (PDB IDs
3QAK and 2YDO) show high similarity, the biggest difference is
found in the residues contacting the ligand. This is due to ligand
differences—additional bulky groups—which push away ECL3
and the extracellular part of TM7 in the 3QAK structure. Addi-
tional differences, also caused by the ligand dissimilarities, occur
in one turn of TM5 (C1855.46), which is pushed away by 1.6Å in
the 3QAK structure. Lack of ECL2 in the 3QAK structure makes
this region impossible to compare. The overall RMSD of these
two structures is 0.5 Å (Figure 5C) (Lebon et al., 2011b; Xu et al.,
2011).
Receptors can additionally be stabilized by ligands, which was
extensively studied for turkey β1 adrenergic receptor (Warne
et al., 2011). The thermostabilized receptor was preferentially in
the inactive state, but could still couple to G proteins after acti-
vation by agonist, although the activation energy barrier is pre-
dicted to be considerably higher than for the wild-type receptor.
All determined structures are very similar to the one determined
with the bound antagonist cyanopindolol as expected for a recep-
tor mutant stabilized preferentially in the inactive state. Agonist
binding, however, induced a 1Å contraction of the catecholamine
binding pocket relative to the structure with bound antagonist
(Warne et al., 2011). Overall, insertion of mutations does not
seem to alter GPCR structures; the published structures of adeno-
sine A2A and neurotensin receptor 1 with and without stabilizing
mutations show high similarity (RMSD= 0.5 Å).
Pharmacological Effects of Mutations on
Turkey β1-Adrenergic Receptor
The pharmacological effects of stabilization have been extensively
studied for thermostabilized turkey β1-adrenergic receptor. It
was shown that deletions of N- and C-termini as well as residues
in the loops (β36 deletions, Warne et al., 2009) did not affect lig-
and binding which is consistent with the view that the N- and
C-terminus and most of cytoplasmic loop 3 do not interact with
the ligand-binding pocket (Baker et al., 2011). Insertion of ther-
mostabilizing mutations, however, reduced the affinity of all lig-
ands approximately tenfold with some of the most efficacious
agonists showing an even higher reduction. Previous ligand bind-
ing data (Serrano-Vega et al., 2008) showed that cyanopindolol
and dihydroalprenolol bound to both versions of the receptor
with similar affinities, while binding of the agonists isoprenaline
and noradrenaline was reduced dramatically. This difference in
ligand binding behavior is likely to be related to the differences
in the environment both sets of the experiments were performed
in (Serrano-Vega et al., 2008; Baker et al., 2011). Isoprenaline,
adrenaline and noradrenaline were able to stimulate activation
of thermostabilized turkey β1-adrenergic receptor though much
higher concentrations were needed to achieve the response in the
thermostabilized version (Baker et al., 2011).
Properties and Uses of Stabilized GPCRs
While structure determination of GPCRs with fusion proteins
required special crystallization techniques, namely lipidic cubic
phase (LCP) crystallization, the structures of conformationally
thermostabilized or evolved receptors could be determined
using crystals obtained in vapor diffusion set-ups. In addition,
crystal structures of receptors bound to weak ligands were only
obtained with conformationally thermostabilized receptors so
far (Congreve et al., 2014). Conformational thermostabilization
increases receptor homogeneity and stability in a wider range of
detergents which in turn facilitates crystallization (Congreve and
Marshall, 2010).
One of the main problems for biophysical characterization
of GPCRs is their inherent instability, loss of native structure
upon solubilization and low conformational homogeneity.
Conformationally thermostabilized receptors, however, show
high activity and conformational homogeneity which results in
good quality data obtained from biophysical experiments such
as surface plasmon resonance (SPR) even when small ligands
are used (Rich et al., 2011). Binders can be rapidly identified and
ranked according to their affinity and kinetics (Congreve et al.,
2011). Furthermore, SPR can be used for biophysical mapping
of the ligand binding site. Ligand-binding site residues are
identified, mutated and screened vs. an array of structurally and
pharmacologically different ligands. Since a thermostabilized
receptor is used as a basis for mutations, high activity and native
conformation are ensured. This approach gives insights on
ligand interaction with the receptor and shows which residues
affect binding of different ligands. These data can be used for
identification of selective compounds in fragment-based drug
discovery (Zhukov et al., 2011).
Fragment-based drug discovery with nuclear magnetic reso-
nance (NMR) experiments have been hindered by the limited
availability of receptor and the nonspecific partitioning of ligands
into detergent micelles. In target-immobilized NMR screening
(TINS), thermostabilized receptors solve the problem of avail-
ability of active receptor. (Congreve et al., 2011). Binding of mix-
tures of three to eight fragments of limited size (<300 Da) and
low affinity (>1µM) is then monitored with 1D 1H NMR spec-
tra (Chen et al., 2012a). Since spin relaxation is far more efficient
in unbound fragments, fragment binding can be detected by loss
of signal.
A great advantage of conformationally thermostabilized
receptors in fragment-based drug discovery is the prospective
identification of fragments which selectively bind receptor active
states and therefore development of functional agonist (Congreve
et al., 2011).
Generation of therapeutic antibodies against GPCRs
is often hindered by the lack of sufficient amounts of
stable, homogeneous, native-state protein. Conformation-
ally thermostabilization of GPCRs may present a very good
tool for antibody generation, since the protein can be made in
larger quantities and is stable in short-chain detergents which
do not mask most relevant epitopes. Furthermore, the receptors
can be stabilized in antagonist or agonist-bound forms which
allows raising of antibodies against specific GPCR conformations
(Hutchings et al., 2010).
Conclusions
Conformational thermostabilization of many different receptors
using alanine/leucine scanning or directed evolution has shown
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that point mutations are a valuable tool for GPCR structural
biology and biophysics. A relatively large fraction (5–12%) of ala-
nine mutations in scanning mutagenesis led to the stabilization
of the receptors, suggesting that it is likely that many receptors
could be stabilized by this approach.
Stabilization by point mutations in combination with the
truncation of the flexible parts of the receptor has led to the
successful crystallization and structure determination of several
receptors including human adenosine A2A receptor, rat neu-
rotensin receptor 1 and turkey β1-adrenergic receptor. The sta-
bilizing mutations can also be combined with a fusion partner
approach therefore expanding the repertoire of approaches which
can be used to obtain receptor structure. Designed mutations
facilitated crystallization of human β2-adrenergic receptor, sero-
tonin receptors 5-HT1B and 5-HT2B as well as chemokine recep-
tor CXCR4 and constitutively active mutations found for many
diseases may facilitate structure determination of active-state
GPCRs or their G-protein complexes. Addition of mutations
is certainly a very powerful technique which can complement
all other techniques to stabilize the receptors for structural and
biophysical characterization.
The exact molecular reasons for why a particular mutation
is stabilizing are not always obvious. In this work, we proposed
four categories of stabilizing mutations based on their role in
the protein ranging from direct to indirect contribution to the
activation mechanism to local stabilization of the structure and
facilitate interactions with the lipid or detergent environment.
The classification certainly furthers our understanding of the
molecular basis for stabilization by mutations and may help in
predicting mutations in the future.
One might hope that in the future it might be possible
to design thermostabilizing mutations, computationally predict
them or transfer them from other receptors, or that the devel-
opment of technology would reduce the effort of finding sta-
bilizing mutations to the point that it would become a widely
used approach in GPCR and other unstable dynamic proteins
structural and biophysical studies.
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